Affymax folds after drug withdrawal


Biotech firm Affymax is to be dissolved after post-marketing reports of serious hypersensitivity reactions prompted it to recall its anaemia drug Omontys (peginesatide).

An investigation in conjunction with its marketing partner Takeda found no quality or manufacturing issues with Omontys. However, it also failed to identify any specific root cause for the allergic reactions, so the companies were left with no option but to withdraw the product. Takeda has broken off its marketing agreement with Affymax, effective from 10 September and, subject to shareholder approval, the company will be liquidated .

Omontys is a PEGylated peptide drug used to treat anaemia caused by chronic kidney disease.


Related Content

Chemistry's grand challenges

28 August 2013 Premium contentFeature

news image

What are the big problems for the next generation of chemists to work on? Mark Peplow takes up the gauntlet

Anarchy in the proteome

29 July 2011 Premium contentFeature

news image

15 years ago, the idea that proteins might be functional without a well-ordered 3D structure was heretical. But Michael Gross...

Most Read

Wind-powered lighting is almost a breeze

13 August 2014 Research

news image

Mechanoluminescent materials seen in a new light

History of King Richard III written in his teeth

18 August 2014 Research

news image

Chemical analysis of isotope signatures in monarch's remains provide insight into his life

Most Commented

Why can we walk on custard?

12 July 2012 Research

news image

Scientists take a closer look at how shear-thickening fluids respond to impacts

Photon pinball identifies chemicals from afar

13 August 2014 Research

news image

Samples turned into random Raman lasers beam their secrets from over a kilometre away